Athira Pharma Inc. (ATHA): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATHA Stock Price Chart Interactive Chart >
ATHA Price/Volume Stats
| Current price | $9.21 | 52-week high | $23.64 |
| Prev. close | $8.85 | 52-week low | $7.56 |
| Day low | $8.77 | Volume | 378,800 |
| Day high | $9.73 | Avg. volume | 292,153 |
| 50-day MA | $10.79 | Dividend yield | N/A |
| 200-day MA | $11.13 | Market Cap | 346.63M |
Athira Pharma Inc. (ATHA) Company Bio
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.
Latest ATHA News From Around the Web
Below are the latest news stories about Athira Pharma Inc that investors may wish to consider to help them evaluate ATHA as an investment opportunity.
Athira Pharma's Alzheimer's therapy ATH-1017 shows promise in phase 1 studyAthira Pharma (NASDAQ:ATHA) reported phase 1 trial of fosgonimeton (ATH-1017) in healthy volunteers and patients with Alzheimer’s disease. The data was published in The Journal of Alzheimer's Disease. The study included 48 healthy young male volunteers in a single ascending dose cohort; 29 healthy elderly volunteers in a multiple ascending dose cohort;... |
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer''s DiseaseFosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer''s disease patients Fosgonimeton was well-tolerated across all dose levels and showed dose-proportional pharmacokinetics and encouraging pharmacodynamic activity Announces fosgonimeton as World Health Organization''s recommended international nonproprietary name for ATH-1017 BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer''s D... |
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual MeetingOral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for neuropsychiatric conditions BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that preclinical data for the active |
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's DiseaseFosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was well-tolerated across all dose levels and showed dose-proportional pharmacokinetics and encouraging pharmacodynamic activity Announces fosgonimeton as World Health Organization’s recommended international nonproprietary name for ATH-1017 BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDA |
Laird Norton Trust Company, Llc Buys iShares National Muni Bond ETF, iShares Core S&P 500 ...Investment company Laird Norton Trust Company, Llc (Current Portfolio) buys iShares National Muni Bond ETF, iShares Core S&P 500 ETF, Airbnb Inc, ACV Auctions Inc, Athira Pharma Inc, sells MSCI USA ESG Select ETF, Vanguard S&P 500 ETF, iShares S&P 500 Growth ETF, Vanguard Growth ETF, FlexShares Global Quality FlexShares Global Qualit during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Laird Norton Trust Company, Llc. |
ATHA Price Returns
| 1-mo | -11.70% |
| 3-mo | -0.97% |
| 6-mo | -32.18% |
| 1-year | -53.81% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -29.32% |
| 2021 | -61.96% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...